Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...

Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose ...

Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...

Tardive dyskinesia is a drug-induced neurological disorder characterized by involuntary movements of the face and body. The condition develops as a side effect of long-term use of antipsychotics and ...

Summary: Researchers have uncovered a new understanding of levodopa-induced dyskinesia, a common side effect in Parkinson’s patients, revealing that the motor cortex disconnects rather than directly ...